Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 2, 2012 ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Down By 5.75% ($0.28) From $4.870 After BUYINS.NET Report Predicted Weakness After Earning
November 2, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, October 31st 2012 stating that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=ziop&id=323652
At the time this story was written, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is Down By 5.75% ($0.28) From $4.870 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of a portfolio of cancer drugs in North America. Its products under various stages of development and trials include Palifosfamide for the treatment of sarcoma, lymphoma, testicular, and other cancers; Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers; and Indibulin, an oral tubulin binding agent that targets mitosis and cancer cell migration. The company has license agreements with DEKK-Tec, Inc.; and Baxter Healthcare Corporation, as well as a collaboration agreement Harmon Hill, LLC. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com